Microvascular complications and diabetic retinopathy: Recent advances and future implications

Future Medicinal Chemistry

Volumn 5, Issue 3, 2013, Pages 301-314

  Barot, Megha ^a   Gokulgandhi, Mitan R ^a   Patel, Sulabh ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CGC 11047; CGC 11093; CGC 11144; CGC 11150; COMBRETASTATIN A4; DEXAMETHASONE; DOBESILATE CALCIUM; E10030; FIBROBLAST GROWTH FACTOR 2; IMATINIB; IMISOPASEM MANGANESE; MIDOSTAURIN; N (5,6 DIHYDRO 6 OXO 2 PHENANTHRIDINYL) 2 DIMETHYLAMINOACETAMIDE; N [4 METHYL 3 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINO]PHENYL]BENZAMIDE; PEGAPTANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; POLYAMINE DERIVATIVE; PROTEIN; RANIBIZUMAB; RECOMBINANT PROTEIN; RUBOXISTAURIN; THIOCTIC ACID; THROMBOSPONDIN; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR TARGETING AGENT; VASOHIBIN; VOLOCIXIMAB;

APOPTOSIS; BACTERIAL EYE INFECTION; BIOLOGICAL ACTIVITY; BLOOD RETINA BARRIER; CATARACT; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CILIARY DISK; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE SEVERITY; DNA DAMAGE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXTRACELLULAR MATRIX; HUMAN; IC 50; IN VITRO STUDY; INTRAOCULAR PRESSURE; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; OXIDATIVE STRESS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA BLOOD FLOW; RETINA BLOOD VESSEL; RETINA CAPILLARY; RETINA DEGENERATION; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; REVIEW; SIDE EFFECT; TREATMENT DURATION; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

ANIMALS; ANTIOXIDANTS; DIABETIC RETINOPATHY; HUMANS; MICROVESSELS; MITOCHONDRIA; PROTEIN KINASE INHIBITORS; RETINA; RETINAL VESSELS; STEROIDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84874701768     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.206     Document Type: Review

References (141)

1. Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: clues towards understanding pathogenesis? Eye (Lond.) 23(7), 1496-1508 (2009).
2. Gardner TW, Antonetti DA, Barber AJ, Lanoue KF, Levison SW. Diabetic retinopathy: more than meets the eye. Surv. Ophthalmol. 47(Suppl. 2), S253-S262 (2002).
3. Strom C, Sander B, Klemp K, Aiello LP, Lund-Andersen H, Larsen M. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 46(10), 3855-3858 (2005).
4. Durham JT, Herman IM. Microvascular modifications in diabetic retinopathy. Curr. Diab. Rep. 11(4), 253-264 (2011).
5. Wong TY, Klein R, Sharrett AR et al. Retinal arteriolar narrowing and risk of diabetes mellitus in middle-aged persons. JAMA 287(19), 2528-2533 (2002).
6. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 47(6), 859-866 (1998).
7. Kim JH, Jun HO, Yu YS, Kim KW. Inhibition of protein kinase C delta attenuates blood-retinal barrier breakdown in diabetic retinopathy. Am. J. Pathol. 176(3), 1517-1524 (2010).
8. Mcgahon MK, Dash DP, Arora A et al. Diabetes downregulates large-conductance Ca2+-activated potassium beta 1 channel subunit in retinal arteriolar smooth muscle. Circ. Res. 100(5), 703-711 (2007).
9. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125(9), 1591-1598 (1998).
10. Orlidge A, D'amore PA. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells. J. Cell Biol. 105(3), 1455-1462 (1987).
11. Geraldes P, Hiraoka-Yamamoto J, Matsumoto M et al. Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat. Med. 15(11), 1298-1306 (2009).
12. Joussen AM, Poulaki V, Le ML et al. A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J. 18(12), 1450-1452 (2004).
13. Joussen AM, Poulaki V, Qin W et al. Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am. J. Pathol. 160(2), 501-509 (2002).
14. Alder VA, Su EN, Yu DY, Cringle SJ, Yu PK. Diabetic retinopathy: early functional changes. Clin. Exp. Pharmacol. Physiol. 24(9-10), 785-788 (1997).
15. Roy S, Cagliero E, Lorenzi M. Fibronectin overexpression in retinal microvessels of patients with diabetes. Invest. Ophthalmol. Vis. Sci. 37(2), 258-266 (1996).
16. Das A, Frank RN, Zhang NL, Samadani E. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening - prevention by an aldose reductase inhibitor. Exp. Eye Res. 50(3), 269-280 (1990).
17. Barot M, Gokulgandhi MR, Mitra AK. Mitochondrial dysfunction in retinal diseases. Curr. Eye Res. 36(12), 1069-1077 (2011).
18. Hussain N, Ghanekar Y, Kaur I. The future implications and indications of anti-vascular endothelial growth factor therapy in ophthalmic practice. Indian J. Ophthalmol. 55(6), 445-450 (2007).
19. Aiello LP. Angiogenic pathways in diabetic retinopathy. N. Engl. J. Med. 353(8), 839-841 (2005).
20. Watanabe D, Suzuma K, Matsui S et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N. Engl. J. Med. 353(8), 782-792 (2005).
21. Watanabe D, Suzuma K, Suzuma I et al. Vitreous levels of angiopoietin 2 and vascular endothelial growth factor in patients with proliferative diabetic retinopathy. Am. J. Ophthalmol. 139(3), 476-481 (2005).
22. Aiello LP, Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331(22), 1480-1487 (1994).
23. Santhan Gopal KS. Increased levels of vascular endothelial growth factor in aqueous humor of patients with diabetic retinopathy: is it the whole truth? Indian J. Ophthalmol. 59(5), 405-406 (2011).
24. Figueroa MS, Contreras I, Noval S. Anti-angiogenic drugs as an adjunctive therapy in the surgical treatment of diabetic retinopathy. Curr. Diabetes Rev. 5(1), 52-56 (2009).
25. Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr. Opin. Ophthalmol. 18(6), 502-508 (2007).
26. Veritti D, Sarao V, Lanzetta P. Neovascular age-related macular degeneration. Ophthalmologica 227(Suppl. 1), 11-20 (2012).
27. Beutel J, Ziemssen F, Luke M, Partsch M, Bartz-Schmidt KU, Gelisken F. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results. Int. Ophthalmol. 30(1), 15-22 (2010).
28. Bahar I, Yeung SN, Sella R, Slomovic A. Anterior segment uses of bevacizumab. Curr. Opin. Ophthalmol. 23(4), 303-316 (2012).
29. Carifi G. Intravitreal bevacizumab for pseudophakic cystoid macular edema. Eur. J. Ophthalmol. 22(3), 513 (2012).
30. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 113(10), 1695 (2006).
31. Scott IU, Edwards AR, Beck RW et al. A Phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114(10), 1860-1867 (2007).
32. Cunningham ET Jr, Adamis AP, Altaweel M et al. A Phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112(10), 1747-1757 (2005).
33. Ng EW, Adamis AP. Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases. Ann. NY Acad. Sci. 1082, 151-171 (2006).
34. Giuliari GP, Guel DA, Gonzalez VH. Pegaptanib sodium for the treatment of proliferative diabetic retinopathy and diabetic macular edema. Curr. Diabetes Rev. 5(1), 33-38 (2009).
35. Boyer DS, Faber D, Gupta S et al. Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 31(5), 915-923 (2011).
36. Haller JA, Kuppermann BD, Blumenkranz MS et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch. Ophthalmol. 128(3), 289-296 (2010).
37. Zhang X, Bao S, Lai D, Rapkins RW, Gillies MC. Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 57(4), 1026-1033 (2008).
38. Massin P, Audren F, Haouchine B et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 111(2), 218-224; discussion 224-225 (2004).
39. Beck RW, Edwards AR, Aiello LP et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch. Ophthalmol. 127(3), 245-251 (2009).
40. Diabetic Retinopathy Clinical Research Network. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 115(9), 1447-1449 (2008).
41. Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26(9), 2653-2664 (2003).
42. Ishii H, Jirousek MR, Koya D et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272(5262), 728-731 (1996).
43. Aiello LP, Clermont A, Arora V, Davis MD, Sheetz MJ, Bursell SE. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients. Invest. Ophthalmol. Vis. Sci. 47(1), 86-92 (2006).
44. Comer GM, Ciulla TA. Pharmacotherapy for diabetic retinopathy. Curr. Opin. Ophthalmol. 15(6), 508-518 (2004).
45. Sheetz MJ, Aiello LP, Shahri N, Davis MD, Kles KA, Danis RP. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6 year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2). Retina 31(6), 1053-1059 (2011).
46. Aiello LP, Vignati L, Sheetz MJ et al. Oral protein kinase C beta inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1392 eyes) with diabetic retinopathy in the protein kinase C beta inhibitor-diabetic retinopathy study and the protein kinase c beta inhibitor-diabetic retinopathy study 2. Retina 31(10), 2084-2094 (2011).
47. Campochiaro PA. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest. Ophthalmol. Vis. Sci. 45(3), 922-931 (2004).
48. Aylward GW. Progressive changes in diabetics and their management. Eye (Lond.) 19(10), 1115-1118 (2005).
49. Harhaj NS, Antonetti DA. Regulation of tight junctions and loss of barrier function in pathophysiology. Int. J. Biochem. Cell Biol. 36(7), 1206-1237 (2004).
50. Robison WG Jr, Kador PF, Kinoshita JH. Early retinal microangiopathy: prevention with aldose reductase inhibitors. Diabet. Med. 2(3), 196-199 (1985).
51. Kowluru RA, Chan PS. Oxidative stress and diabetic retinopathy. Exp. Diabetes Res. 2007, 43603 (2007).
52. Packer L, Kraemer K, Rimbach G. Molecular aspects of lipoic acid in the prevention of diabetes complications. Nutrition 17(10), 888-895 (2001).
53. Kowluru RA. Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death. Antioxid. Redox Signal 7(11-12), 1581-1587 (2005).
54. Lin J, Bierhaus A, Bugert P et al. Effect of R-(+)-alpha-lipoic acid on experimental diabetic retinopathy. Diabetologia 49(5), 1089-1096 (2006).
55. Kowluru RA, Odenbach S. Effect of long-term administration of alpha-lipoic acid on retinal capillary cell death and the development of retinopathy in diabetic rats. Diabetes 53(12), 3233-3238 (2004).
56. Obrosova IG, Fathallah L, Liu E, Nourooz-Zadeh J. Early oxidative stress in the diabetic kidney: effect of dl-alpha-lipoic acid. Free Radic. Biol. Med. 34(2), 186-195 (2003).
57. Berthet P, Farine JC, Barras JP. Calcium dobesilate: pharmacological profile related to its use in diabetic retinopathy. Int. J. Clin. Pract. 53(8), 631-636 (1999).
58. Tejerina T, Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen. Pharmacol. 31(3), 357-360 (1998).
59. Ribeiro ML, Seres AI, Carneiro AM et al. Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Graefes Arch. Clin. Exp. Ophthalmol. 244(12), 1591-1600 (2006).
60. Nambu H, Nambu R, Melia M, Campochiaro PA. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44(8), 3650-3655 (2003).
61. Galbraith SM, Chaplin DJ, Lee F et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res. 21(1A), 93-102 (2001).
62. Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57(10), 1829-1834 (1997).
63. Ren X, Dai M, Lin LP, Li PK, Ding J. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent. Br. J. Pharmacol. 156(8), 1228-1238 (2009).
64. Caballero S, Yang R, Grant MB, Chaqour B. Selective blockade of cytoskeletal actin remodeling reduces experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 52(5), 2490-2496 (2011).
65. Durham JT, Herman IM. Inhibition of angiogenesis in vitro: a central role for beta-actin dependent cytoskeletal remodeling. Microvasc. Res. 77(3), 281-288 (2009).
66. Pasquier E, Honore S, Braguer D. Microtubule-targeting agents in angiogenesis: where do we stand? Drug Resist. Updat. 9(1-2), 74-86 (2006).
67. Subbiah IM, Lenihan DJ, Tsimberidou AM. Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist 16(8), 1120-1130 (2011).
68. Campochiaro PA, Glaser BM. Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch. Ophthalmol. 103(4), 576-579 (1985).
69. Seo MS, Okamoto N, Vinores MA et al. Photoreceptor-specific expression of platelet-derived growth factor-B results in traction retinal detachment. Am. J. Pathol. 157(3), 995-1005 (2000).
70. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10(2), 141-148 (2007).
71. Jo N, Mailhos C, Ju M et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am. J. Pathol. 168(6), 2036-2053 (2006).
72. Ozaki H, Seo MS, Ozaki K et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am. J. Pathol. 156(2), 697-707 (2000).
73. Kwak N, Okamoto N, Wood JM, Campochiaro PA. VEGF is major stimulator in model of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 41(10), 3158-3164 (2000).
74. Seo MS, Kwak N, Ozaki H et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am. J. Pathol. 154(6), 1743-1753 (1999).
75. Labelle AL, Hamor RE, Townsend WM et al. Ophthalmic lesions in neonatal foals evaluated for nonophthalmic disease at referral hospitals. J. Am. Vet. Med. Assoc. 239(4), 486-492 (2011).
76. Boyer DS. The ophthotech anti-PDGF in AMD study group. Combined inhibition of platelet derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD) - results of a Phase I study. Invest. Ophthalmol. Vis. Sci. 50, e-Abstract 1260 (2009).
77. Smith LE, Shen W, Perruzzi C et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat. Med. 5(12), 1390-1395 (1999).
78. Smith LE, Kopchick JJ, Chen W et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 276(5319), 1706-1709 (1997).
79. Ruberte J, Ayuso E, Navarro M et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J. Clin. Invest. 113(8), 1149-1157 (2004).
80. Oshima Y, Deering T, Oshima S et al. Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor. J. Cell Physiol. 199(3), 412-417 (2004).
81. Devi TS, Singh LP, Hosoya K, Terasaki T. GSK-3beta/CREB axis mediates IGF-1-induced ECM/adhesion molecule expression, cell cycle progression and monolayer permeability in retinal capillary endothelial cells: Implications for diabetic retinopathy. Biochim. Biophys. Acta 1812(9), 1080-1088 (2011).
82. Shing Y, Folkman J, Haudenschild C, Lund D, Crum R, Klagsbrun M. Angiogenesis is stimulated by a tumor-derived endothelial cell growth factor. J. Cell Biochem. 29(4), 275-287 (1985).
83. Shing Y, Folkman J, Sullivan R, Butterfield C, Murray J, Klagsbrun M. Heparin affinity: purification of a tumor-derived capillary endothelial cell growth factor. Science 223(4642), 1296-1299 (1984).
84. Sato Y, Rifkin DB. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J. Cell Biol. 107(3), 1199-1205 (1988).
85. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc. Natl Acad. Sci. USA 83(19), 7297-7301 (1986).
86. Moscatelli D, Presta M, Rifkin DB. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis, and migration. Proc. Natl Acad. Sci. USA 83(7), 2091-2095 (1986).
87. Yamada H, Yamada E, Ando A et al. Fibroblast growth factor-2 decreases hyperoxia-induced photoreceptor cell death in mice. Am. J. Pathol. 159(3), 1113-1120 (2001).
88. Ozaki H, Okamoto N, Ortega S et al. Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization. Am. J. Pathol. 153(3), 757-765 (1998).
89. Yamada H, Yamada E, Kwak N et al. Cell injury unmasks a latent proangiogenic phenotype in mice with increased expression of FGF2 in the retina. J. Cell. Physiol. 185(1), 135-142 (2000).
90. Dike LE, Ingber DE. Integrin-dependent induction of early growth response genes in capillary endothelial cells. J. Cell Sci. 109 (Pt 12), 2855-2863 (1996).
91. Umeda N, Kachi S, Akiyama H et al. Suppression and regression of choroidal neovascularization by systemic administration of an alpha5beta1 integrin antagonist. Mol. Pharmacol. 69(6), 1820-1828 (2006).
92. Orecchia A, Lacal PM, Schietroma C, Morea V, Zambruno G, Failla CM. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin. J. Cell Sci. 116(Pt 17), 3479-3489 (2003).
93. Luna J, Tobe T, Mousa SA, Reilly TM, Campochiaro PA. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab. Invest. 75(4), 563-573 (1996).
94. Zahn G, Vossmeyer D, Stragies R et al. Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch. Ophthalmol. 127(10), 1329-1335 (2009).
95. Barkan D, Chambers AF. beta1-integrin: a potential therapeutic target in the battle against cancer recurrence. Clin. Cancer Res. 17(23), 7219-7223 (2011).
96. Park JE, Keller GA, Ferrara N. The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol. Biol. Cell 4(12), 1317-1326 (1993).
97. Vlodavsky I, Korner G, Ishai-Michaeli R, Bashkin P, Bar-Shavit R, Fuks Z. Extracellular matrix-resident growth factors and enzymes: possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev. 9(3), 203-226 (1990).
98. Vlodavsky I, Folkman J, Sullivan R et al. Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc. Natl Acad. Sci. USA 84(8), 2292-2296 (1987).
99. Ramchandran R, Dhanabal M, Volk R et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV. comparison to endostatin. Biochem. Biophys. Res. Commun. 255(3), 735-739 (1999).
100. O'reilly MS, Boehm T, Shing Y et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2), 277-285 (1997).
101. Kamphaus GD, Colorado PC, Panka DJ et al. Canstatin, a novel matrix-derived inhibitor of angiogenesis and tumor growth. J. Biol. Chem. 275(2), 1209-1215 (2000).
102. Colorado PC, Torre A, Kamphaus G et al. Anti-angiogenic cues from vascular basement membrane collagen. Cancer Res. 60(9), 2520-2526 (2000).
103. Auricchio A, Behling KC, Maguire AM et al. Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents. Mol. Ther. 6(4), 490-494 (2002).
104. Mori K, Gehlbach P, Ando A, Mcvey D, Wei L, Campochiaro PA. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest. Ophthalmol. Vis. Sci. 43(7), 2428-2434 (2002).
105. Mori K, Gehlbach P, Yamamoto S et al. AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 43(6), 1994-2000 (2002).
106. Mori K, Duh E, Gehlbach P et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J. Cell. Physiol. 188(2), 253-263 (2001).
107. Lai CC, Wu WC, Chen SL et al. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest. Ophthalmol. Vis. Sci. 42(10), 2401-2407 (2001).
108. Watanabe K, Hasegawa Y, Yamashita H et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J. Clin. Invest. 114(7), 898-907 (2004).
109. Sekiyama E, Saint-Geniez M, Yoneda K et al. Heat treatment of retinal pigment epithelium induces production of elastic lamina components and antiangiogenic activity. FASEB J. 26(2), 567-575 (2012).
110. Uno K, Bhutto IA, Mcleod DS, Merges C, Lutty GA. Impaired expression of thrombospondin-1 in eyes with age related macular degeneration. Br. J. Ophthalmol. 90(1), 48-54 (2006).
111. Campochiaro PA, Nguyen QD, Shah SM et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a Phase I clinical trial. Hum. Gene Ther. 17(2), 167-176 (2006).
112. Shen J, Yang X, Xiao WH, Hackett SF, Sato Y, Campochiaro PA. Vasohibin is up-regulated by VEGF in the retina and suppresses VEGF receptor 2 and retinal neovascularization. FASEB J. 20(6), 723-725 (2006).
113. Hosaka T, Kimura H, Heishi T et al. Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am. J. Pathol. 175(1), 430-439 (2009).
114. Kimura H, Miyashita H, Suzuki Y et al. Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood 113(19), 4810-4818 (2009).
115. Yamashita H, Abe M, Watanabe K et al. Vasohibin prevents arterial neointimal formation through angiogenesis inhibition. Biochem. Biophys. Res. Commun 345(3), 919-925 (2006).
116. Gehlbach P, Demetriades AM, Yamamoto S et al. Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier. Hum. Gene Ther. 14(2), 129-141 (2003).
117. Lai CM, Brankov M, Zaknich T et al. Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization. Hum. Gene Ther. 12(10), 1299-1310 (2001).
118. Honda M, Sakamoto T, Ishibashi T, Inomata H, Ueno H. Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration. Gene Ther. 7(11), 978-985 (2000).
119. Hangai M, Moon YS, Kitaya N et al. Systemically expressed soluble Tie2 inhibits intraocular neovascularization. Hum. Gene Ther. 12(10), 1311-1321 (2001).
120. Takahashi T, Nakamura T, Hayashi A et al. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells. Am. J. Ophthalmol. 130(6), 774-781 (2000).
121. Takahashi K, Saishin Y, Silva RL et al. Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment. FASEB J. 17(8), 896-898 (2003).
122. Mori K, Ando A, Gehlbach P et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am. J. Pathol. 159(1), 313-320 (2001).
123. Kanwar M, Chan PS, Kern TS, Kowluru RA. Oxidative damage in the retinal mitochondria of diabetic mice: possible protection by superoxide dismutase. Invest. Ophthalmol. Vis. Sci. 48(8), 3805-3811 (2007).
124. Kowluru RA, Abbas SN. Diabetes-induced mitochondrial dysfunction in the retina. Invest. Ophthalmol. Vis. Sci. 44(12), 5327-5334 (2003).
125. Madsen-Bouterse SA, Zhong Q, Mohammad G, Ho YS, Kowluru RA. Oxidative damage of mitochondrial DNA in diabetes and its protection by manganese superoxide dismutase. Free Radic. Res. 44(3), 313-321 (2010).
126. Mohammad G, Kowluru RA. Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction. Lab. Invest. 90(9), 1365-1372 (2010).
127. Nassar T, Kadery B, Lotan C, Da'as N, Kleinman Y, Haj-Yehia A. Effects of the superoxide dismutase-mimetic compound tempol on endothelial dysfunction in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 436(1-2), 111-118 (2002).
128. Coppey LJ, Gellett JS, Davidson EP et al. Effect of M40403 treatment of diabetic rats on endoneurial blood flow, motor nerve conduction velocity and vascular function of epineurial arterioles of the sciatic nerve. Br. J. Pharmacol. 134(1), 21-29 (2001).
129. Kowluru RA, Zhong Q. Beyond AREDS. is there a place for antioxidant therapy in the prevention/treatment of eye disease? Invest. Ophthalmol. Vis. Sci. 52(12), 8665-8671 (2011).
130. Sugawara R, Hikichi T, Kitaya N et al. Peroxynitrite decomposition catalyst, FP15, and poly(ADP-ribose) polymerase inhibitor, PJ34, inhibit leukocyte entrapment in the retinal microcirculation of diabetic rats. Curr. Eye Res. 29(1), 11-16 (2004).
131. Kowluru RA, Tang J, Kern TS. Abnormalities of retinal metabolism in diabetes and experimental galactosemia. VII. Effect of long-term administration of antioxidants on the development of retinopathy. Diabetes 50(8), 1938-1942 (2001).
132. Zheng L, Szabo C, Kern TS. Poly(ADP-ribose) polymerase is involved in the development of diabetic retinopathy via regulation of nuclear factor-kappaB. Diabetes 53(11), 2960-2967 (2004).
133. Lima E Silva R, Saishin Y, Akiyama H et al. Suppression and regression of choroidal neovascularization by polyamine analogues. Invest. Ophthalmol. Vis. Sci. 46(9), 3323-3330 (2005).
134. Lima E Silva R, Kachi S, Akiyama H et al. Trans-scleral delivery of polyamine analogs for ocular neovascularization. Exp. Eye Res. 83(5), 1260-1267 (2006).
135. Diabetic retinopathy: future demand to be driven by agents that improve visual acuity. http://decisionresources.com/Products-and Services/Report.Aspx?R= Dbaspd1408
136. Hoffmann-La Roche Ltd. www.roche.com/Investors/Ir-Update/ Inv-Update-2011-2006-29.Htm
137. Study evaluating the safety and response of fosbretabulin in asian patients with polypoidal choroidal vasculopathy (PCV). http://clinicaltrials. gov/ct2/show/ NCT01023295
138. Safety and efficacy study of combretastatin A4 phosphate to treat patients with choroidal neovascularization secondary to pathologic myopia. http://clinicaltrials.gov/ct2/show/ NCT01423149
139. A safety and efficacy study of E10030 (anti-PDGF pegylated aptamer) plus lucentis for neovascular age-related macular degeneration. http:// clinicaltrials.gov/ct2/show/ NCT01089517
140. A Phase 1 safety study of single and repeated doses of JSM6427 (intravitreal injection) to treat AMD. http://clinicaltrials.gov/ct2/show/ NCT00536016
141. A Phase 1 ascending and parallel group trial to establish the safety, tolerability and pharmacokinetics profile of volociximab (alpha 5 beta 1 integrin antagonist) in subjects with neovascular age-related macular degeneration. http://clinicaltrials.gov/show/NCT00782093